113. Muscular dystrophy Clinical trials / Disease details

Clinical trials : 646 / Drugs : 471 - (DrugBank : 105) / Drug target genes : 59 - Drug target pathways : 170

13 trials found

diseases per page:

Showing 1 to 10 of 13 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2020-000699-39-NL (EUCTR)	28/06/2021	09/02/2021	Evaluation of Pamrevlumab for the Treatment of Ambulatory Patients Affected by Duchenne Muscular Dys ...	A Phase 3, Randomized, Double-Blind, Trial of Pamrevlumab (FG-3019)or Placebo in Combination with Sy ...	Ambulatory Duchenne Muscular Dystrophy MedDRA version: 20.0;Level: PT;Classification code 10013801;T ...	Product Name: Pamrevlumab Product Code: FG-3019 INN or Proposed INN: PAMREVLUMAB	FibroGen, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: no Male: yes	70	Phase 3	United States;France;Canada;Spain;Belgium;Austria;Australia;Netherlands;United Kingdom;Italy
2	EUCTR2020-000699-39-AT (EUCTR)	26/04/2021	29/01/2021	Evaluation of Pamrevlumab for the Treatment of Ambulatory Patients Affected Duchenne Muscular Dystro ...	A Phase 3, Randomized, Double-Blind, Trial of Pamrevlumab (FG-3019)or Placebo in Combination with Sy ...	Ambulatory Duchenne Muscular Dystrophy MedDRA version: 20.0;Level: PT;Classification code 10013801;T ...	Product Name: Pamrevlumab Product Code: FG-3019 INN or Proposed INN: PAMREVLUMAB	FibroGen, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: no Male: yes	70	Phase 3	United States;France;Canada;Spain;Belgium;Australia;Austria;Netherlands;United Kingdom;Italy
3	EUCTR2020-000699-39-IT (EUCTR)	19/04/2021	04/06/2021	Evaluation of Pamrevlumab for the Treatment of Ambulatory Patients Affected by Duchenne Muscular Dys ...	A Phase 3, Randomized, Double-Blind, Trial of Pamrevlumab (FG-3019)or Placebo in Combination with Sy ...	Ambulatory Duchenne Muscular Dystrophy MedDRA version: 20.0;Level: PT;Classification code 10013801;T ...	Product Name: Pamrevlumab Product Code: [FG-3019] INN or Proposed INN: PAMREVLUMAB	FIBROGEN	NULL	Authorised-recruitment may be ongoing or finished			Female: no Male: yes	70	Phase 3	France;United States;Czechia;Canada;Spain;Belgium;Austria;Australia;Netherlands;United Kingdom;Switz ...
4	EUCTR2020-000698-26-AT (EUCTR)	02/02/2021	17/08/2020	A Phase 3, Randomized, Double-Blind, Trial of Pamrevlumab (FG-3019)or Placebo in Combination with Sy ...	A Phase 3, Randomized, Double-Blind, Trial of Pamrevlumab (FG-3019)or Placebo in Combination with Sy ...	Non-ambulatory Duchenne Muscular Dystrophy MedDRA version: 20.0;Level: PT;Classification code 100138 ...	Product Name: Pamrevlumab Product Code: FG-3019 INN or Proposed INN: PAMREVLUMAB	FibroGen, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: no Male: yes	96	Phase 3	United States;Czechia;Spain;Austria;Israel;Italy;Switzerland;United Kingdom;France;Czech Republic;Ca ...
5	EUCTR2020-000698-26-NL (EUCTR)	20/01/2021	08/09/2020	Evaluation of Pamrevlumab for the Treatment of Male Patients Affected by Non-ambulatory Duchenne Mus ...	A Phase 3, Randomized, Double-Blind, Trial of Pamrevlumab (FG-3019)or Placebo in Combination with Sy ...	Non-ambulatory Duchenne Muscular Dystrophy MedDRA version: 20.0;Level: PT;Classification code 100138 ...	Product Name: Pamrevlumab Product Code: FG-3019 INN or Proposed INN: PAMREVLUMAB	FibroGen, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: no Male: yes	90	Phase 3	United States;Czechia;Spain;Austria;Israel;Italy;Switzerland;United Kingdom;France;Czech Republic;Ca ...
6	EUCTR2020-000698-26-IT (EUCTR)	28/12/2020	06/11/2020	Evaluation of Pamrevlumab for the Treatment of Male Patients Affected by Non-ambulatory Duchenne Mus ...	A Phase 3, Randomized, Double-Blind, Trial of Pamrevlumab (FG-3019)or Placebo in Combination with Sy ...	Non-ambulatory Duchenne Muscular Dystrophy MedDRA version: 20.0;Level: PT;Classification code 100138 ...	Product Name: Pamrevlumab Product Code: [FG-3019] INN or Proposed INN: PAMREVLUMAB	FIBROGEN	NULL	Authorised-recruitment may be ongoing or finished			Female: no Male: yes	90	Phase 3	United States;Czechia;Slovakia;Spain;Turkey;Austria;Israel;Italy;Switzerland;United Kingdom;France;C ...
7	EUCTR2020-000698-26-GB (EUCTR)	16/12/2020	14/10/2020	Evaluation of Pamrevlumab for the Treatment of Male Patients Affected by Non-ambulatory Duchenne Mus ...	A Phase 3, Randomized, Double-Blind, Trial of Pamrevlumab (FG-3019)or Placebo in Combination with Sy ...	Non-ambulatory Duchenne Muscular Dystrophy MedDRA version: 20.0;Level: PT;Classification code 100138 ...	Product Name: Pamrevlumab Product Code: FG-3019 INN or Proposed INN: PAMREVLUMAB	FibroGen, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: no Male: yes	90	Phase 3	United States;Slovakia;Spain;Turkey;Austria;Israel;United Kingdom;Italy;Switzerland;France;Czech Rep ...
8	EUCTR2020-000698-26-CZ (EUCTR)	15/12/2020	19/08/2020	Evaluation of Pamrevlumab for the Treatment of Male Patients Affected by Non-ambulatory Duchenne Mus ...	A Phase 3, Randomized, Double-Blind, Trial of Pamrevlumab (FG-3019)or Placebo in Combination with Sy ...	Non-ambulatory Duchenne Muscular Dystrophy MedDRA version: 20.0;Level: PT;Classification code 100138 ...	Product Name: Pamrevlumab Product Code: FG-3019 INN or Proposed INN: PAMREVLUMAB	FibroGen, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: no Male: yes	92	Phase 3	France;United States;Czechia;Czech Republic;Belgium;Spain;Austria;Netherlands;United Kingdom;Italy;S ...
9	NCT04632940 (ClinicalTrials.gov)	December 11, 2020	12/11/2020	Phase 3 Trial of Pamrevlumab or Placebo in Combination With Systemic Corticosteroids in Participants ...	A Phase 3, Randomized, Double-Blind, Trial of Pamrevlumab (FG-3019)or Placebo in Combination With Sy ...	Duchenne Muscular Dystrophy	Drug: Pamrevlumab;Drug: Placebo;Drug: Corticosteroids	FibroGen	NULL	Active, not recruiting	6 Years	11 Years	Male	70	Phase 3	United States;Australia;Austria;Belgium;Canada;China;France;Italy;Netherlands;Spain;United Kingdom;S ...
10	NCT04371666 (ClinicalTrials.gov)	July 30, 2020	29/4/2020	Phase 3 Trial of Pamrevlumab or Placebo With Systemic Corticosteroids in Participants With Non-ambul ...	A Phase 3, Randomized, Double-Blind, Trial of Pamrevlumab (FG-3019)or Placebo in Combination With Sy ...	Duchenne Muscular Dystrophy	Drug: Pamrevlumab;Drug: Placebo;Drug: Corticosteroids	FibroGen	NULL	Active, not recruiting	12 Years	N/A	Male	92	Phase 3	United States;Australia;Austria;Belgium;Canada;China;Czechia;France;Israel;Italy;Netherlands;Spain;S ...

First Previous1 2Next Last